# A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection

> **NCT00006154** · PHASE3 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 165 (estimated)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Indinavir sulfate
- **DRUG:** Ritonavir
- **DRUG:** Abacavir sulfate
- **DRUG:** Efavirenz
- **DRUG:** Stavudine
- **DRUG:** Didanosine
- **DRUG:** Aldesleukin

## Key facts

- **NCT ID:** NCT00006154
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 165 (ESTIMATED)
- **Last updated:** 2013-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006154, "A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00006154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*